ID   WM983A
AC   CVCL_6808
SY   WM-983A; WM 983A; WM983-A; WC00048
DR   cancercelllines; CVCL_6808
DR   Cell_Model_Passport; SIDM01396
DR   Coriell; WC00048
DR   Cosmic; 686405
DR   Cosmic; 928685
DR   Cosmic; 1155272
DR   Cosmic; 1155565
DR   Cosmic; 1155569
DR   Cosmic; 1303081
DR   GEO; GSM109047
DR   GEO; GSM185208
DR   GEO; GSM185209
DR   GEO; GSM186503
DR   GEO; GSM186504
DR   Progenetix; CVCL_6808
DR   Rockland; WM983A-01-0001
DR   Wikidata; Q54994345
RX   PubMed=2068080;
RX   PubMed=2253310;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=18790768;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; PubMed=18632627; Wistar).
CC   Omics: Transcriptome analysis by microarray.
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: Amelogenin: X,Y->X, CSF1PO: 10,11->11, D13S317: 11,12->12, D5S818: 10,11->11 and D7S820: 10,11->11.
CC   Discontinued: Coriell; WC00048; probable.
ST   Source(s): Wistar
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 11,12
ST   D18S51: 14
ST   D19S433: 10,14
ST   D21S11: 29,32.2
ST   D2S1338: 25,27
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 11
ST   D8S1179: 8,13
ST   FGA: 20,23
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_6809 ! WM983B
OI   CVCL_A338 ! WM983C
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 23
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028; PMCID=PMC52015;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235; PMCID=PMC2615688;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431; PMCID=PMC2651569;
RA   Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B.,
RA   Egyhazi Brage S., Hansson J., Wu H., King A.J., Van Belle P.,
RA   Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.;
RT   "Increased cyclin D1 expression can mediate BRAF inhibitor resistance
RT   in BRAF V600E-mutated melanomas.";
RL   Mol. Cancer Ther. 7:2876-2883(2008).
//